Capcell pak c18 mgii

HPLC was performed according to JECFA [32 ], using a Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan) and ODS C18 columns (length: 250 mm; inner diameter: 4.6 mm; particle size: 5 μm) (Capcell Pak C18 MGII; Shiseido Co., Ltd., Tokyo, Japan) with a UV–VIS detector (210 nm). The mobile phase was a 32:68 (v/v) mixture of ACN and 10 mmol/L sodium phosphate buffer (pH 2.6) at a flow rate of 1.0 mL/min, and the column temperature was maintained at 40 °C. Standard steviol glycoside solutions were prepared at concentrations of 100–1000 mg/kg. The standard and sample solutions (20 µL) were injected into the HPLC system. Steviol glycosides were identified based on the retention times, using the standard mixture as a reference, and the peak areas were measured. Each solution was analyzed in triplicate, and the mean value was used for analysis.

The concentration was measured via the high-performance liquid chromatography (HPLC) method, which was previously described [19 (link)]. In brief, a Capcell Pak C18 MG II (250 mm × 4.6 mm ID; Shiseido, Tokyo, Japan) HPLC column was used for drug analysis. The mobile phase was a mixture of 0.5% KH2PO4 (adjusted to pH 3.5), acetonitrile, and methanol (55:25:20). The flow rate was 0.5 mL/min at ambient temperature, and sample detection was carried out at 250 nm. A 10 μL solution of gefitinib (10 ng), as an internal standard for the quantitation of osimertinib and AZ5104, was added to the 100 μL plasma or CSF sample, followed by dilution of the sample with 900 μL of water and vortexing for 30 s. This mixture was applied to an Oasis hydrophilic–lipophilic balance extraction cartridge that had been previously activated with methanol and water (1.0 mL each). The cartridge was then washed with 1.0 mL of water and 1.0 mL of 40% methanol in water followed by elution with 0.4 mL of 100% methanol and then 1.0 mL of 100% acetonitrile. The residue was dissolved in 20 μL of methanol, 20 μL of the mobile phase was added to the sample, and a 20 μL aliquot of the sample was then processed on the HPLC system.

A Capcell pak C18 MG II from Shiseido Co., Ltd was used as a column and the detection wavelength was 254 nm. The mobile phase for cytarabine and fluorouracil was 10 mmol/L phosphate buffer (pH 5.0):acetonitrile (95:5) and 50 mmol/L phosphate buffer (pH 5.0):methanol (85:15), respectively. The flow rate was 1 mL/min and the resulting chromatogram was analyzed using Chromato-PRO software from Run Time Corporation. The ozone-exposed and non-exposed control anticancer drugs on the plates were recovered by wiping the plates with cotton containing purified water. The reproducibility of HPLC and recovery rate of anticancer drug from the plate were examined prior to the ozone exposure experiment and was satisfactory for further experiments. The non-treated control levels of the anticancer drugs were estimated as 100 %.

Marker compounds of WS-5 were detected using the HPLC system Shiseido with photodiode array detector. The elution profile was monitored at 254 nm using a column temperature of 40°C. Chromatography was performed using a Capcell Pak C18 MG II (250 Χ 4.6 mm, 5 μM; Shiseido Co., Ltd., Tokyo, Japan). The mobile phase was composed of 0.1% trifluoroacetic acid in water (solvent A) and 0.1% trifluoroacetic acid in acetonitrile (solvent B). The gradient program was 0-10 min, 100% of solvent A; 10-13 min, 90% of solvent A; 13-20 min, 60% of solvent A; 20-25 min, 60% of solvent A; 25-35 min, 50% of solvent A; 35-40 min, 50% of solvent A; 40-45 min, 55% of solvent A; 45-55 min, 30% of solvent A; 55-60 min, 30% of solvent A with a flow rate of 1 ml/min and the injection volume was 10 μl.